Revenue grew 7.8% to AUD 13.2B, underlying EBITDA rose 7.3% to AUD 624M, and EPS increased 6.8%. FY 2025 guidance targets AUD 575–600M EBITDA, with cost savings and new pharmacy revenues expected to offset the end of the Chemist Warehouse contract.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.